Peptides

Electroencephalography (EEG) monitoring
#Carnyx Therapeutics #Peptides #Sleep disorders

Carnyx Therapeutics unveils oral sleep candidate

Carnyx Therapeutics has unveiled CNYX-005, its lead oral sleep candidate, alongside preclinical findings showing increased total sleep time and non-rapid eye movement (NREM) sleep in aged animal models.  In the study, aged rats administered with CNYX-005 showed an approximately 1.5- to 2-hour increase in total sleep time… Read More

#News

Peptide
#App note #Peptides #Thermal stability testing

App Note: Peptide formulation with multi-parameter stability insights

Peptide therapeutics, while one of the fastest growing drug modalities, are challenging to formulate, due to heir conformational flexibility, propensity for aggregation and fibrillation, and sensitivity to pH. In this Application Note from Nanotemper, learn how to: Simultaneously assess thermal and colloidal stability to reveal early self-association propensity Compare finished-product… Read More

#News

#Collaboration #Drug delivery #Nanexa #Novo Nordisk #Peptides

Novo and Nanexa agree €1.165 billion drug delivery deal

A new agreement grants Novo a global exclusive license to Nanexa’s PharmaShell atomic layer deposition (ALD) drug delivery technology platform for certain therapeutic peptide drugs in indications including obesity, type 2 diabetes and other cardiometabolic diseases.  The collaboration includes development of long-acting injectable formulations with different administration-frequency… Read More

#Business & Investment #News

Cancer cells
#Cancer Research UK #Clinical trials #Oncology #Peptides

Cancer Research UK leads global trial of rare cancer therapy 

Cancer Research UK is leading a group of partners launching a global Phase II trial into rare adrenal gland cancer.  Biotechnology company Cytovation and the Norwegian Cancer Society (NCS) have joined forces with Cancer Research UK for the trial of people with advanced adrenocortical carcinoma (ACC), a rare and… Read More

#News #Trending News

Lungs
#Kither Biotech #Peptides #Phase I trial #Respiratory

Kither completes Phase I trial of inhaled peptide therapy

Kither Biotech has announced the successful completion of its Phase I clinical study of KIT2014 for respiratory diseases in healthy participants.  “We are pleased to report the successful completion of this first-in-human Phase I study with KIT2014, a significant milestone for Kither Biotech,” said Dr Dimitrios Goundis,… Read More

#News

#Alzheimer's #Brain cancer #Cardiovascular disease #Cholesterol #Colorectal cancer #Dementia #Ebola virus #Eli Lilly #Gene therapy #Genetic profiling #Immunology / Virology & Vaccines #Peptides #Stem cells #University of Reading #Vaccines

DDW Highlights: 2 June 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, a UK group accelerated efforts to develop a vaccine for Ebolavirus. Elsewhere,… Read More

#Podcasts

#Alzheimer's #Brain cancer #Cardiovascular disease #Cholesterol #Colorectal cancer #Dementia #Ebola virus #Eli Lilly #Gene therapy #Genetic profiling #Immunology / Virology & Vaccines #Peptides #Stem cells #University of Reading #Vaccines

This week in Drug Discovery (25–29 May) 

News round-up for 25–29 May by Bruno Quinney, Content Team at DDW.  This week, a UK group has accelerated efforts to develop a vaccine for Ebolavirus. Elsewhere, significant findings in colorectal and brain cancer could shape future cancer treatments.  The top stories:    UK group steps… Read More

#News

Peptide
#Alzheimer's #Dementia #Peptides

Peptide ‘shuttles’ could transform Alzheimer’s treatment 

Research into the use of peptide ‘shuttles’ has been praised for its potential to overcome barriers in Alzheimer’s and dementia treatment.  Peter Davies, Deputy Director at the Texas A&M Health Institute of Biosciences and Technology, and his colleagues have been awarded a Dementia and Alzheimer’s Initiative (DARI)… Read More

#Editor's Choice #News

Peptides
#Artificial intelligence (AI) #Drug discovery #Peptides #Webinar

Last chance to register: Discover cyclic peptide drug design

Cyclic peptides have a special power in the therapeutic space — they’re larger and more specific than small molecules, and more permeable and cost-effective than antibodies. These qualities enable them to conquer two of the biggest challenges in modern drug development: prosecuting flat intracellular protein-protein interactions (PPIs) and achieving oral… Read More

Webinar date:
Supported by BioDuro
#News

Peptide
#Artificial intelligence (AI) #Drug discovery #Peptides #Webinar

Register now: A deep dive into the cyclic peptide discovery landscape

Cyclic peptides have a special power in the therapeutic space — they’re larger and more specific than small molecules, and more permeable and cost-effective than antibodies. These qualities enable them to conquer two of the biggest challenges in modern drug development: prosecuting flat intracellular protein-protein interactions (PPIs) and achieving oral… Read More

Webinar date:
Supported by BioDuro
#News

Artificial intelligence
#Artificial intelligence (AI) #Drug discovery #Peptides #Webinar

Cyclic peptide drug design: From experimental discovery to AI-driven computation

Cyclic peptides have a special power in the therapeutic space — they’re larger and more specific than small molecules, and more permeable and cost-effective than antibodies. These qualities enable them to conquer two of the biggest challenges in modern drug development: prosecuting flat intracellular protein-protein interactions (PPIs) and achieving oral… Read More

Webinar date:
Supported by BioDuro
#News

Peptides
#Artificial intelligence (AI) #Drug discovery #Peptides #Webinar

Webinar: The art and science of cyclic peptide drug design

Cyclic peptides have a special power in the therapeutic space — they’re larger and more specific than small molecules, and more permeable and cost-effective than antibodies. These qualities enable them to conquer two of the biggest challenges in modern drug development: prosecuting flat intracellular protein-protein interactions (PPIs) and achieving oral… Read More

Webinar date:
Supported by BioDuro
#News

Peptides
#Artificial intelligence (AI) #Drug discovery #Peptides #Webinar

The art and science of cyclic peptide drug design: From experimental discovery to AI-driven computation

Cyclic peptides have a special power in the therapeutic space — they’re larger and more specific than small molecules, and more permeable and cost-effective than antibodies. These qualities enable them to conquer two of the biggest challenges in modern drug development: prosecuting flat intracellular protein-protein interactions (PPIs) and achieving oral… Read More

Webinar date:
Supported by BioDuro
#Webinars

#Biotech #India #Peptides

Commercial peptide facility to support biotech programmes 

An expanded commercial peptide facility in India will open to support emerging biotech programmes.  CDMO Neuland Laboratories will open its new commercial peptide facility in the summer of 2026 at its 17-acre Bonthapally manufacturing campus, with further capacity expansions planned as client demand increases.   The first of four… Read More

#News

#ABPI #Alzheimer's #Clinical trial #Metabolomics #National Institute for Health and Care Excellence (NICE) #Neurodegenerative disorders #Peptides #UK government #US government

DDW Highlights: 9 December 2025

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, a trade agreement between the UK and the US promised to support… Read More

#Podcasts

#ABPI #Alzheimer's #Clinical trial #Metabolomics #National Institute for Health and Care Excellence (NICE) #Neurodegenerative disorders #Peptides #UK government #US government

This week in Drug Discovery (1 – 5 December) 

News round-up for 1 – 5 December by Bruno Quinney, Content Team at DDW.  This week in DDW, a trade agreement between the UK and the US promises to support the life sciences industry and secure access to drugs. Elsewhere, novel therapies could break new ground in treating neurodegenerative diseases.  The… Read More

#News